P53, DEC1 and DCR2 appear to increase in expression in the more advanced stages of the development of breast cancer, peaking at the premalignant DCIS stage, followed by a slight drop or plateauing in the invasive lesion. Here, TNFRSF10D is linked to breast carcinoma.